Indevus/Pliva Sanctura clears FDA
Indevus/Pliva's Sanctura (trospium) clears FDA May 28 for treatment of overactive bladder. Product will be launched in third quarter. Sanctura is first new molecular entity approved for overactive bladder since Pharmacia's Detrol (tolterodine) in 1998 [Editor's Note: More coverage of the Sanctura approval appears in 1"The Pink Sheet" DAILY. Visit our website, www.ThePinkSheetDAILY.com, to sign up for a free trial.]....
You may also be interested in...
Indevus/Pliva's Sanctura will enter the overactive bladder market during the third quarter
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.